Insider Buying: Vivani Medical (NASDAQ:VANI) Director Acquires $92,938.85 in Stock

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 85,265 shares of the firm’s stock in a transaction that occurred on Thursday, November 19th. The shares were bought at an average price of $1.09 per share, for a total transaction of $92,938.85. Following the acquisition, the director directly owned 37,111,299 shares in the company, valued at $40,451,315.91. This trade represents a 0.23% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Gregg Williams also recently made the following trade(s):

  • On Wednesday, November 18th, Gregg Williams bought 33,169 shares of Vivani Medical stock. The shares were bought at an average cost of $1.05 per share, for a total transaction of $34,827.45.
  • On Tuesday, November 17th, Gregg Williams purchased 29,929 shares of Vivani Medical stock. The stock was bought at an average price of $1.05 per share, for a total transaction of $31,425.45.
  • On Monday, November 16th, Gregg Williams purchased 2,100 shares of Vivani Medical stock. The stock was acquired at an average price of $1.01 per share, with a total value of $2,121.00.
  • On Friday, November 13th, Gregg Williams bought 48,100 shares of Vivani Medical stock. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $47,619.00.

Vivani Medical Price Performance

NASDAQ VANI opened at $1.09 on Friday. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66. The company has a fifty day moving average of $1.16 and a 200 day moving average of $1.23. The company has a market capitalization of $98.32 million, a PE ratio of -3.41 and a beta of 2.51.

Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.

Analyst Ratings Changes

Several analysts have weighed in on VANI shares. Wall Street Zen lowered Vivani Medical from a “hold” rating to a “sell” rating in a report on Sunday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.75.

View Our Latest Analysis on VANI

About Vivani Medical

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

Read More

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.